Genelux (GNLX) Cash & Equivalents (2022 - 2026)

Genelux's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.8% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 32.8% YoY), while the FY2025 annual figure was $12.2 million, up 42.62% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.3 million, down from $12.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $40.4 million in Q2 2024, with the low at $397000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $13.0 million (2025), against an average of $17.3 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 1895.97% in 2023, then plunged 86.36% in 2025.
• Genelux's Cash & Equivalents stood at $397000.0 in 2022, then surged by 1895.97% to $7.9 million in 2023, then grew by 8.09% to $8.6 million in 2024, then jumped by 42.62% to $12.2 million in 2025, then dropped by 24.09% to $9.3 million in 2026.
• Business Quant data shows GNLX's Cash & Equivalents at $9.3 million in Q1 2026, $12.2 million in Q4 2025, and $4.7 million in Q3 2025.